Systemic nutritional-inflammatory status and its dynamic changes as predictive biomarkers for neoadjuvant immunotherapy efficacy in locally advanced MSS/pMMR colorectal cancer

Background Locally advanced microsatellite stable or mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC) shows heterogeneous responses to neoadjuvant immunotherapy. Host systemic nutritional-inflammatory status and its dynamic changes may affect antitumor immune efficacy. This study aimed to explore their predictive value for neoadjuvant immunotherapy efficacy. Method A total of 342 locally advanced MSS/pMMR CRC patients receiving neoadjuvant PD-1 inhibitor plus CAPOX regimen (capecitabine plus oxaliplatin) were retrospectively enrolled. Patients were divided into treatment-sensitive (TRG 0-1) and treatment-resistant (TRG 2-3) groups, then randomly assigned to training and validation sets at a 7:3 ratio. LASSO and multivariable logistic regression were used to screen independent predictors and construct a nomogram. Model performance was assessed by ROC, calibration curves, decision-curve analysis (DCA), and Bootstrap internal validation. Results The treatment-sensitive group had 105 patients (30.7%). Multivariable analysis identified age (OR = 0.96, 95% CI: 0.93–0.99), post- neoadjuvant treatment LogCEA (OR = 0.23, 95% CI: 0.12–0.44), and a 50-unit increase in the advanced lung cancer inflammation index (ΔALI) during neoadjuvant immunotherapy (OR = 1.296, 95% CI: 1.173–1.433) as independent predictors of efficacy. The model and the nomogram constructed based on the above variables achieved AUCs of 0.82 (95% CI: 0.76–0.87) in the training cohort (n = 240) and 0.73 (95% CI: 0.60–0.82) in the validation cohort (n = 102), with a negative predictive value (NPV) of 0.79 (95% CI: 0.70-0.86) in the validation cohort. The C-index after Bootstrap internal calibration was 0.82 (95% CI: 0.76–0.88), and the calibration curve demonstrated good agreement between predicted probabilities and observed outcomes. DCA confirmed favorable clinical net benefit across a wide range of threshold probabilities. Sensitivity analysis excluding the confounding effect of treatment cycles confirmed the robustness of the model. The final nomogram provided a practical reference tool for individualized prediction of neoadjuvant immunotherapy efficacy. Conclusion Dynamic ΔALI serves as an independent predictor for neoadjuvant immunotherapy efficacy. The nomogram based on nutritional-inflammatory indices exhibits acceptable discrimination and calibration. Given its limited positive predictive performance, it serves as an auxiliary preoperative rule-out tool to identify patients unlikely to derive neoadjuvant immunotherapy benefit and support individualized therapeutic decision-making.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-17
DOI
https://doi.org/10.3389/fonc.2026.2034174
Primary Topic
Inflammatory Biomarkers in Disease Prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Systemic nutritional-inflammatory status and its dynamic changes as predictive biomarkers for neoadjuvant immunotherapy efficacy in locally advanced MSS/pMMR colorectal cancer

Minglin Lin, Zhiyuan Xia, Zizhuo Wang, Dongchao Liu et al.
6 links
Frontiers in Oncology
Inflammatory Biomarkers in Disease Prognosis
article

Systemic nutritional-inflammatory status and its dynamic changes as predictive biomarkers for neoadjuvant immunotherapy efficacy in locally advanced MSS/pMMR colorectal cancer

Minglin Lin, Zhiyuan Xia, Zizhuo Wang, Dongchao Liu, Ming Qiu, Haining Chen, Xihua Xie, Shen Pang, bo Lan, Minghui Lin, Sen Zhang
article en

Abstract

Background Locally advanced microsatellite stable or mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC) shows heterogeneous responses to neoadjuvant immunotherapy. Host systemic nutritional-inflammatory status and its dynamic changes may affect antitumor immune efficacy. This study aimed to explore their predictive value for neoadjuvant immunotherapy efficacy. Method A total of 342 locally advanced MSS/pMMR CRC patients receiving neoadjuvant PD-1 inhibitor plus CAPOX regimen (capecitabine plus oxaliplatin) were retrospectively enrolled. Patients were divided into treatment-sensitive (TRG 0-1) and treatment-resistant (TRG 2-3) groups, then randomly assigned to training and validation sets at a 7:3 ratio. LASSO and multivariable logistic regression were used to screen independent predictors and construct a nomogram. Model performance was assessed by ROC, calibration curves, decision-curve analysis (DCA), and Bootstrap internal validation. Results The treatment-sensitive group had 105 patients (30.7%). Multivariable analysis identified age (OR = 0.96, 95% CI: 0.93–0.99), post- neoadjuvant treatment LogCEA (OR = 0.23, 95% CI: 0.12–0.44), and a 50-unit increase in the advanced lung cancer inflammation index (ΔALI) during neoadjuvant immunotherapy (OR = 1.296, 95% CI: 1.173–1.433) as independent predictors of efficacy. The model and the nomogram constructed based on the above variables achieved AUCs of 0.82 (95% CI: 0.76–0.87) in the training cohort (n = 240) and 0.73 (95% CI: 0.60–0.82) in the validation cohort (n = 102), with a negative predictive value (NPV) of 0.79 (95% CI: 0.70-0.86) in the validation cohort. The C-index after Bootstrap internal calibration was 0.82 (95% CI: 0.76–0.88), and the calibration curve demonstrated good agreement between predicted probabilities and observed outcomes. DCA confirmed favorable clinical net benefit across a wide range of threshold probabilities. Sensitivity analysis excluding the confounding effect of treatment cycles confirmed the robustness of the model. The final nomogram provided a practical reference tool for individualized prediction of neoadjuvant immunotherapy efficacy. Conclusion Dynamic ΔALI serves as an independent predictor for neoadjuvant immunotherapy efficacy. The nomogram based on nutritional-inflammatory indices exhibits acceptable discrimination and calibration. Given its limited positive predictive performance, it serves as an auxiliary preoperative rule-out tool to identify patients unlikely to derive neoadjuvant immunotherapy benefit and support individualized therapeutic decision-making.

Frontiers in OncologyVol. 16
First Affiliated Hospital of GuangXi Medical University (CN), Jingzhou Central Hospital (CN)
Natural Science Foundation of Guangxi Zhuang Autonomous Region, National Natural Science Foundation of China, Natural Science Foundation of Guangxi Province, Guangxi Medical University
Good health and well-being
Inflammatory Biomarkers in Disease Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon